Global Haemophilia market to expand with over 6% CAGR through 2023

November 11, 2019


According to the latest study titled ‘Global Haemophilia Market - Analysis By Type (Haemophilia A, Haemophilia B), By Treatment (On-demand, Prophylaxis), By Region, By Country (2019 Edition): Opportunities and Forecasts (2013-2023): By Region (North America, Europe, APAC, ROW), By Country (U.S, Canada, Germany, UK, Japan, China, India, Brazil)’ available with Market Study Report LLC, the global haemophilia market is estimated to grow with a CAGR of 6.84% during the period 2018-2023.  
 

Haemophilia is a genetic disorder, resulting in failure of blood clot. Factors such as improved life expectancy of hemophiliac patients, lower inhibitor formation in severe cases and emergence of new treatment therapies are influencing the growth of haemophilia market.
 

Additionally, growing incidences of hemorrhages, dental and arthropaedic surgeries, laceration and abrasion, epistaxis, and increasing individual healthcare expenditures also contribute to the rise of haemophilia market. Other factors aiding the market growth are constant development across medical infrastructure and government initiatives towards increasing healthcare awareness.
 

The study encompasses details about segmental shares and expansion strategies adopted by manufacturers, alongside the drivers, trends, and restraints impacting the market growth. It analyzes the market thoroughly to understand the growth patterns and forecasts investment recommendations.
 

Based on product type, the haemophilia market is segmented into haemophilia A and haemophilia B, wherein former segment is predicted to hold majority share over the forecast period. While based on treatment type, the industry is divided into on-demand and prophylaxis.
 

Request sample copy of this Report@ https://www.marketstudyreport.com/request-a-sample/1689406/
 

Considering the geographical landscape, the global haemophilia market is fragmented into regions including Europe, North America, Asia Pacific, and rest of world, with key focus on countries like, Germany, U.S., Canada, Japan, U.K, India, Brazil, and China. However, in 2018, North America dominated the haemophilia market, whereas Asia Pacific region is presumed to witness lucrative growth opportunities in the forthcoming years, cites the report.
 

The key players of haemophilia market are Novo Nordisk, Bayer, Roche, Pfizer, Catalyst BioSciences, Aptevo Therapeutics, Shire, Dimension Therapeutics, Alnylam Pharmaceuticals, and CSL Behring.


Frequently Asked Questions (FAQ) :

Factors such as improving life expectancy of hemophiliac patients, lower inhibitor formation in severe cases and emergence of new treatment therapies are influencing the growth of haemophilia market. Additionally, growing incidences of hemorrhages, dental and arthropaedic surgeries, laceration and abrasion, epistaxis, and increasing individual healthcare expenditures also contribute to the rise of haemophilia market.
Based on product type, the haemophilia market is segmented into haemophilia A and haemophilia B. While based on treatment type, the industry is divided into on- demand and prophylaxis.
North America dominated the global haemophilia market in 2018, claims the report.
The competitors of haemophilia market are Novo Nordisk, Bayer, Roche, Pfizer, Catalyst BioSciences, Aptevo Therapeutics, Shire, Dimension Therapeutics, Alnylam Pharmaceuticals, and CSL Behring.